The field of pharmaceuticals is witnessing a transformative phase with the introduction of large-volume injectors (LVIs), which promise to be Game-changers in administering high doses of medication. At the heart of this evolution, the discussion led by Mark DeStefano at Pharmapack Europe 2024 stands out as a critical analysis of the integration challenges posed by LVIs.
Mark DeStefano: Navigating the Future of Pharmaceuticals
As the director of new device technology at Teva Pharmaceuticals, DeStefano’s expertise is invaluable. His presentation shed light on the intricacies of infusing these complex devices into the pharmaceutical mainstream, thus charting a course for future development and integration of LVIs.Facing the Challenges of LVIs Integration
The comprehensive approach outlined by DeStefano at the conference emphasized the need for a thorough understanding of the hurdles associated with LVIs. This drive to overcome the technological and practical challenges will be instrumental in ensuring that LVIs become a reliable facet of pharmaceutical regimens.By focusing on the evolution of drug delivery methods and the promise LVIs hold, the discourse at Pharmapack Europe 2024 has indeed set the stage for an exciting future in healthcare innovations.
